| Literature DB >> 27504587 |
Jolien Suurmond1, Justine Calise2, Susan Malkiel1, Betty Diamond3.
Abstract
IgG anti-DNA antibodies are both diagnostic and pathogenic for systemic lupus erythematosus (SLE). They contribute to tissue inflammation through direct tissue binding and to systemic inflammation through activation of Toll-like receptors by nucleic acid-containing immune complexes. IgG DNA-reactive antibodies originate when B cell tolerance mechanisms are impaired. The heterogeneous immune perturbations in SLE lead to the survival and activation of DNA-reactive B cells in various B cell subsets at distinct stages of B cell maturation and differentiation. We propose that the spectrum of B cell alterations and failed tolerance mechanisms for DNA-reactive B cells in lupus patients is best understood by studying genetic risk alleles. This implies that the B cells producing IgG anti-DNA antibodies and the failed tolerance mechanisms(s) will differ across patients. A better understanding of these differences should lead to better patient stratification, improved outcomes of clinical trials, and the identification of novel therapeutic targets. Copyright ÂEntities:
Mesh:
Substances:
Year: 2016 PMID: 27504587 PMCID: PMC5125853 DOI: 10.1016/j.coi.2016.07.002
Source DB: PubMed Journal: Curr Opin Immunol ISSN: 0952-7915 Impact factor: 7.486